Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia
出版年份 2020 全文链接
标题
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia
作者
关键词
-
出版物
Blood Advances
Volume 4, Issue 17, Pages 4136-4146
出版商
American Society of Hematology
发表日期
2020-09-04
DOI
10.1182/bloodadvances.2020002003
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy and safety of a new intravenous immunoglobulin (Panzyga® ) in chronic immune thrombocytopenia
- (2019) O. Arbach et al. TRANSFUSION MEDICINE
- Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis
- (2019) James F. Howard et al. NEUROLOGY
- Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia
- (2019) Adrian C. Newland et al. AMERICAN JOURNAL OF HEMATOLOGY
- Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex–mediated immune responses
- (2019) L. J. Blumberg et al. Science Advances
- Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials
- (2018) James Bussel et al. AMERICAN JOURNAL OF HEMATOLOGY
- 538 FcRn blockade with SYNT001 for the treatment of pemphigus
- (2018) V.P. Werth et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Emerging Concepts in Immune Thrombocytopenia
- (2018) Maurice Swinkels et al. Frontiers in Immunology
- M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study
- (2018) Leona E. Ling et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Health-related quality of life in adult primary immune thrombocytopenia
- (2018) Hanna Gran Sestøl et al. Expert Review of Hematology
- The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study
- (2017) Peter Kiessling et al. Science Translational Medicine
- Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)
- (2017) Anne Zufferey et al. Journal of Clinical Medicine
- Current Management of Primary Immune Thrombocytopenia
- (2015) Drew Provan et al. ADVANCES IN THERAPY
- Antibody binding to megakaryocytesin vivoin patients with immune thrombocytopenia
- (2015) Donald M Arnold et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro
- (2015) M. Iraqi et al. HAEMATOLOGICA
- Removal Characteristics of Immunoglobulin G Subclasses by Conventional Plasma Exchange and Selective Plasma Exchange
- (2015) Atsushi Ohkubo et al. THERAPEUTIC APHERESIS AND DIALYSIS
- Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro
- (2015) M. Iraqi et al. HAEMATOLOGICA
- Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group
- (2013) F. Rodeghiero et al. BLOOD
- Therapeutic plasma exchange: A technical and operational review
- (2013) Andre A. Kaplan JOURNAL OF CLINICAL APHERESIS
- A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia
- (2011) J. B. Bussel et al. BLOOD
- The ITP syndrome: pathogenic and clinical diversity
- (2009) D. B. Cines et al. BLOOD
- Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
- (2009) James B Bussel et al. LANCET
- Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP
- (2008) J. B. Bussel et al. BLOOD
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started